Most 140-year-old companies are coasting. Johnson & Johnson (JNJ) is restructuring. And that’s the part of the J&J story that rarely gets enough attention.
When people think of this company, they think of dividend checks and baby powder. A steady, predictable blue-chip that you hold forever and never think about. That image is accurate in some ways, but it misses what’s actually happening beneath it.
J&J is actively separating its orthopaedics division, doubling down on oncology, and preparing for a Dec. 8 Enterprise Business Review that could reframe the entire investment thesis for years ahead.
CEO Joaquin Duato just guided the company toward more than $100 billion in annual revenue for the first time in its 140-year history, according to its Q2 2026 results. And the dividend? It just hit 64 consecutive years of increases without missing a beat.
This is not only a legacy company standing still. It’s a legacy company deliberately reshaping itself. And Dec. 8 is when we find out exactly what that reshaping looks like.
Also Read: Johnson & Johnson Latest News and Stories
Why J&J is separating its orthopaedics business
In October 2025, Johnson & Johnson shared plans to spin off its orthopaedics division into a stand-alone publicly traded company called DePuy Synthes. The separation is targeted for completion within 18 to 24 months from that announcement date, subject to board approval and regulatory clearances.
DePuy Synthes isn’t a weak business being discarded. In fact, it’s the world’s largest orthopaedics-focused company, serving a global market worth more than $50 billion and generating approximately $9.2 billion in sales in 2024, according to Johnson & Johnson. Namal Nawana has been appointed to lead it as a stand-alone entity.
More Healthcare/Health:
- One IRA withdrawal can triple your Medicare premium
- UnitedHealth’s earnings comeback hides a risk Wall Street can’t price
- Medicare’s new $50 GLP-1 deal has a catch
So why separate a $9 billion business that’s working? Because J&J is playing a different game now.
The company wants capital, management attention, and investor perception aligned around six faster-growing areas: Oncology, Immunology, Neuroscience, Cardiovascular, Surgery, and Vision.
Orthopaedics, while valuable, grows at a different pace than what J&J is building toward. Spinning it out sharpens focus and may unlock value on both sides of the split.
Related: Johnson & Johnson bets $1 billion on hard-to-treat cancer
My understanding is that this is the same playbook J&J used when it spun off Kenvue, the consumer health business, in 2023. Yes, it works.
The remaining entity trades at a higher multiple because the growth profile improves. DePuy Synthes becomes a focused pure-play that institutional investors can size appropriately. Everyone wins.
Oncology is J&J’s growth engine, and the numbers back it up
If orthopaedics is what J&J is walking away from, oncology is where it’s running toward.
The company is targeting $50 billion in annual oncology drug sales by 2030, according to a Barron’s report. That’s a pretty ambitious number. And the Q2 2026 results actually suggest the trajectory is real.
Innovative Medicine, J&J’s pharmaceutical segment, reported sales of $16.38 billion in Q2 fiscal 2026, up 7.8% year over year (YoY), according to a J&J statement.
The key drivers were DARZALEX, CARVYKTI, TECVAYLI, and RYBREVANT in oncology, besides TREMFYA in immunology.
STELARA declines — expected as biosimilar competition increases — were more than offset by growth across the newer portfolio.
- Total company reported sales surpassed $25.3 billion in Q2, up 6.6% YoY
- Adjusted diluted earnings per share (EPS) came in at $2.90, up 4.7% YoY
- Free cash flow reached approximately $8.7 billion year-to-date
Source: Johnson & Johnson Q2 2026 Results
J&J raised its full-year 2026 guidance following the quarter. The company now expects reported sales of $100.8 billion to $101.4 billion and adjusted diluted EPS of $11.60 to $11.75, up from prior guidance in both cases.
Duato framed the milestone, stating: “Quarterly sales surpassing $25 billion — we are on track to meet our 2026 target of more than $100 billion in annual revenue for the first time in our Company’s 140-year history.”
The talc settlement that cleared a major J&J overhang
Even before looking ahead to December, it’s worth acknowledging what J&J has put behind it. The company offered up to $5.5 billion to settle talc-related lawsuits involving its baby powder, covering approximately 76,000 cases, according to BBC reporting.
J&J has denied that its talc products caused cancer and changed the formula of its baby powder.
Also Read: History of Johnson & Johnson: Timeline and Facts
The settlement provides clearer visibility on future cash demands. That means a meaningful unlock for investors who had been discounting the stock for legal uncertainty.
The proposal requires acceptance by legal firms representing 95% of ovarian cancer claims in state and federal courts before it can be finalized.
Here is why Dec. 8 is the date every J&J investor should mark
J&J’s Enterprise Business Review is scheduled for Dec. 8, 2026. This is where management is expected to deliver a detailed deep dive on long-term growth targets, pipeline execution, and capital allocation as the company tracks toward its goal of double-digit growth by the end of the decade.
The orthopaedics separation timeline, the oncology buildout toward $50 billion, and the post-settlement capital picture all converge at that event. It’s the moment J&J management will either prove the restructuring thesis convincingly or leave investors wanting more.
JNJ shares were trading at $259.24, up 26.66% year to date and 54.91% over the past year, according to Yahoo Finance at the time of this reporting. The S&P 500 returned 13.32% and 22.36% over those same periods. J&J also declared a third-quarter 2026 dividend of $1.34 per share, payable Sept. 8, 2026.
Sixty-four years of dividend growth. A $100 billion revenue milestone. A strategic separation designed to unlock faster growth. Dec. 8 is when J&J makes the full case for what comes next.
Related: J&J’s biotech progress could punish its 2027 profit
